The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
Name
Hyrimoz
Active Substance
adalimumab
Prescription
Medicinal product subject to medical prescription
Type of prescription
ograničeni recept
Distribution
Supply through pharmacies (community)
ATC Code
L04AB04
Marketing status
stavljeno u promet
Shortage status
nema nestašice
Summary of product characteristics (SmPC), labelling and package leaflet (PL)
